Skip to main content

Biocartis, Covance Sign Commercialization Agreement for Idylla

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis has announced that it has signed a commercialization agreement with Covance, the clinical research organization owned by Laboratory Corporation of America, to offer its Idylla platform and oncology assay menu to Covance's global customer base.

According to Biocartis, the agreement provides for placement of Idylla molecular testing instruments at Covance sites to support customer needs for clinical trials and to validate and implement companion diagnostic applications.

The alliance "is another important step in building an ecosystem around Idylla, this time by deploying our Idylla technology in one of the largest laboratory networks used by the pharmaceutical industry to conduct drug development," Biocartis CEO Herman Verrelst said in a statement. "We believe the fully automated and standardized workflow of our Idylla platform can be of significant value, potentially paving the way for new partnerships with pharmaceutical companies in the context of their oncology treatment developments."

Financial details of the agreement were not disclosed.

Biocartis previously partnered with Bristol-Myers Squibb in March to develop a companion diagnostic for several cancer immunotherapies with an initial focus on colorectal cancer.